{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:06:35Z","timestamp":1789545995211,"version":"build-2803163510"},"reference-count":88,"publisher":"Wiley","issue":"18","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000867","name":"Robert Wood Johnson Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000867","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001927","name":"Nile Albright Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001927","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2026,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for patients with gynecologic malignancies. ICIs have led to improved survival outcomes in uterine and cervical cancer, although with only modest success in ovarian cancer. In endometrial cancer, The Cancer Genome Atlas provided the framework for the molecular classification of endometrial cancer, enabling identification of the predominant predictive biomarker: mismatch repair (MMR) status. US Food and Drug Administration approvals for ICI monotherapy and in combination with targeted therapy based on MMR status quickly followed. Further research demonstrated a role for ICIs in combination with chemotherapy regardless of MMR status in the initial treatment of advanced or metastatic disease. In cervical cancer, ICIs are approved for use in combination with chemotherapy\u2010sensitized radiation and in combination with systemic chemotherapy in patients who have recurrent or metastatic disease. In ovarian cancer, the tumor microenvironment, low tumor mutational burden, and the absence of a reliable predictive biomarker have limited the efficacy of ICIs, with most combination approaches failing to demonstrate meaningful benefit. A notable exception is KEYNOTE\u2010B96, a randomized trial of pembrolizumab versus placebo with weekly paclitaxel, with or without bevacizumab, in patients with platinum\u2010resistant ovarian cancer. Continued investigation into predictive biomarkers, resistance mechanisms, and alternative therapeutic targets is critically needed to extend the benefits of immunotherapy to patients with ovarian cancer. In this review, the authors describe the current immunotherapy landscape across gynecologic cancers, highlighting when ICI use is, and is not, supported by the evidence.<\/jats:p>","DOI":"10.1002\/cncr.70611","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:54:28Z","timestamp":1789534468000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["IMMU\u2010NO versus yes: Applicability of immune checkpoint inhibitors in gynecologic cancers"],"prefix":"10.1002","volume":"132","author":[{"given":"William B.","family":"Manning","sequence":"first","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology Massachusetts General Hospital  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia M.","family":"Youssef","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology Massachusetts General Hospital  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6319-1647","authenticated-orcid":false,"given":"Oladapo O.","family":"Yeku","sequence":"additional","affiliation":[{"name":"Mass General Brigham Cancer Institute Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12113"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.101"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.62.3397"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy058"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.74.082803.133243"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2003.04.060"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.519"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01874"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201022\u20103915"},{"key":"e_1_2_9_11_1","unstructured":"US Food and Drug Administration (FDA).FDA grants regular approval to dostarlimab\u2010gxly for dMMR endometrial cancer.2023. Accessed July 5 2026.https:\/\/www.fda.gov\/drugs\/resources\u2010information\u2010approved\u2010drugs\/fda\u2010grants\u2010regular\u2010approval\u2010dostarlimab\u2010gxly\u2010dmmr\u2010endometrial\u2010cancer"},{"key":"e_1_2_9_12_1","volume-title":"FDA Approves Pembrolizumab for Advanced Endometrial Carcinoma","author":"American Society of Clinical Oncology (ASCO)","year":"2022"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02627"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108330"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102025\u2010013713"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201024\u201001326"},{"key":"e_1_2_9_17_1","volume-title":"FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) Burst Edition: FDA approval of Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) for advanced endometrial carcinoma","author":"US Food and Drug Administration (FDA)","year":"2021"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.11.054"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02132"},{"key":"e_1_2_9_20_1","article-title":"FDA approves durvalumab with chemotherapy for mismatch repair deficient primary advanced or recurrent endometrial cancer","author":"US Food and Drug Administration (FDA)","year":"2024","journal-title":"US Food and Drug Administration"},{"key":"e_1_2_9_21_1","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Uterine Neoplasms","author":"National Comprehensive Cancer Network (NCCN)","year":"2026"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302312"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2216334"},{"key":"e_1_2_9_24_1","volume-title":"FDA approves pembrolizumab with chemotherapy for primary advanced or recurrent endometrial carcinoma","author":"US Food and Drug Administration (FDA)","year":"2024"},{"key":"e_1_2_9_25_1","volume-title":"FDA expands endometrial cancer indication for dostarlimab\u2010gxly with chemotherapy","author":"US Food and Drug Administration (FDA)","year":"2024"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(24)01808\u20107"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(24)00317\u20109"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00914"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01265"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(26)00602\u20101"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.virol.2019.10.001"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.5471"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112187"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.21037\/atm\u201020\u20102656"},{"key":"e_1_2_9_35_1","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Cervical Cancer","author":"National Comprehensive Cancer Network (NCCN)","year":"2026"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(24)00088\u20103"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02067"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc\u20102020\u2010001126"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(17)31607\u20100"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(23)02405\u20104"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.31525\/fda1-ucm610572.htm"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(23)00479\u20105"},{"key":"e_1_2_9_44_1","volume-title":"FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 stage III\u2013IVA cervical cancer","author":"US Food and Drug Administration (FDA)","year":"2024"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.5529"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010025\u201067646\u2010z"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010024\u201055200\u20102"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14184458"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32058"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177"},{"key":"e_1_2_9_51_1","volume-title":"FDA approves pembrolizumab with paclitaxel for platinum\u2010resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma","author":"US Food and Drug Administration (FDA)","year":"2026"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.11.017"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz135"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02059"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00334"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201025\u201001210"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201023\u20102249"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.5945"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(21)00342\u20109"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc\u20102021\u2010002933"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2269"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.009"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(21)00216\u20103"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5500"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijgc.2025.102856"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.1916"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.11.020"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0252665"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.3343"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00024"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells9051299"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13277\u2010015\u20103133\u20108"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.3390\/biom16020246"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2019.00160"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392\u2010025\u201002505\u20103"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2026.44.16_suppl.e17588"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104084"},{"key":"e_1_2_9_80_1","volume-title":"FDA Converts to Full Approval Indication for KEYTRUDA\u00ae (pembrolizumab) for Certain Adult and Pediatric Patients With Advanced Microsatellite Instability\u2010High (MSI\u2010H) or Mismatch Repair Deficient (dMMR) Solid Tumors [news release]","author":"Merck & Company, Inc","year":"2023"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.41165"},{"key":"e_1_2_9_82_1","volume-title":"FDA grants accelerated approval to dostarlimab\u2010gxly for dMMR advanced solid tumors","author":"US Food and Drug Administration (FDA)","year":"2021"},{"key":"e_1_2_9_83_1","volume-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","author":"National Comprehensive Cancer Network (NCCN)","year":"2026"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.60637"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201016\u20103215"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2025.04.504"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.106"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.Ccr\u201020\u20100056"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2013.24.3.258"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70611","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.70611","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.70611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T07:40:56Z","timestamp":1789544456000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.70611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":88,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2026,9,15]]}},"alternative-id":["10.1002\/cncr.70611"],"URL":"https:\/\/doi.org\/10.1002\/cncr.70611","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"2026-07-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70611"}}